Jana granted regulatory clearance for Zimmer Biomet stake

Judith Bessette
Julho 17, 2017

First Allied Advisory Services Inc. raised its position in shares of Zimmer Biomet Holdings by 70.6% in the fourth quarter. Over the past twelve months, Zimmer Biomet Holdings, Inc.

Among 23 analysts covering Zimmer Biomet Holdings (NYSE:ZBH), 17 have Buy rating, 2 Sell and 4 Hold. Cleararc Capital Inc. now owns 4,897 shares of the medical equipment provider's stock worth $598,000 after buying an additional 25 shares during the period. Levin Capital Strategies L.P. now owns 556,036 shares of the medical equipment provider's stock worth $57,383,000 after buying an additional 164,132 shares during the period. Finally, GLG LLC raised its stake in shares of Zimmer Biomet Holdings by 6.8% in the fourth quarter. Alpha Windward LLC now owns 1,651 shares of the medical equipment provider's stock worth $202,000 after buying an additional 18 shares during the period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. (ZBH) opened at 132.49 on Friday. The firm has a 50 day moving average of $123.43 and a 200-day moving average of $117.75.

The company has a one year high of $133.21 and a one year low of $95.63.

The P/E ratio is 54.23 and market cap is 26.72B. Point72 Asset Management L.P. now owns 1,053,500 shares of the medical equipment provider's stock worth $128,643,000 after buying an additional 734,500 shares in the last quarter.

06/07/2017 - Zimmer Biomet Holdings, Inc. had its " rating reiterated by analysts at Citigroup. The company had revenue of $1.98 billion during the quarter, compared to analysts' expectations of $1.96 billion. During the same period previous year, the firm earned $2.00 earnings per share. They expect $2.08 earnings per share, down 5.45% or $0.12 from last year's $2.2 per share.

Focus: economistas projetam inflação menor para 2017
As expectativas para o IPCA recuaram de uma alta de 3,38% para outra de 3,29% para 2017 e de 4,24% para 4,20% para 2018. Para o ano que vem a estimativa é que a economia brasileira mostre recuperação ao fechar o ano com alta de 2% no PIB .

The business also recently announced a quarterly dividend, which will be paid on Friday, July 28th. The dividend will be $0.240 per share for the quarter which is $0.96 annualized. This dividend represents a yeild of $0.72 which is the dividend as a percentage of the current share price. The ex-dividend date is Wednesday, June 21st. Zimmer Biomet Holdings's payout ratio is presently 39.67%. Equities analysts forecast that Zimmer Biomet Holdings, Inc. will post $8.52 EPS for the current fiscal year. "(ZBH) Shares Bought by North Star Asset Management Inc." was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and global trademark and copyright law.

TRADEMARK VIOLATION WARNING: "Zimmer Biomet Holdings, Inc". On November 8 the company was rated "Neutral" by Northcoast Research a cut from the previous " rating.

Jana Partners was granted regulatory clearance on Thursday for its purchase of shares in medical device maker Zimmer Biomet Holdings Inc, in a sign that the hedge fund is set to build its stake and press for changes at the company. Guggenheim upgraded shares of Zimmer Biomet Holdings from a "neutral" rating to a "buy" rating and set a $157.00 target price on the stock in a report on Wednesday. Looking back over the past 4 weeks, shares have seen a percentage change of 0.11. Zimmer Biomet Holdings now has an average rating of "Buy" and a consensus target price of $137.19.

In other news, VP Chad F. Phipps sold 6,200 shares of the company's stock in a transaction dated Friday, May 5th. Schafer Cullen Capital Management Inc sold 116,011 shares as The Travelers Companies Inc. Following the completion of the sale, the insider now directly owns 381,886 shares of the company's stock, valued at approximately $44,478,262.42. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. David C. Dvorak, President and CEO disclosed the sale of 87,331 shares of (ZBH). The shares were sold at an average price of $124.56, for a total value of $2,208,573.36. Insiders have sold a total of 111,262 shares of company stock worth $13,103,927 over the last 90 days.

Zimmer Biomet Holdings, Inc., launched on January 12, 2001, is involved in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Outros relatórios LazerEsportes

Discuta este artigo

SIGA O NOSSO JORNAL